This study is testing a drug called YA-101 for people with Multiple System Atrophy (MSA), a rare neurological disorder. Researchers want to see if YA-101 is safe and well-tolerated, and if it might help with MSA symptoms. You could be eligible to join if you are 30 years or older and have a diagnosis of MSA. The study will compare two different doses of YA-101 to a placebo (an inactive substance) to see how participants react. The main goal is to track any side effects that happen between the start of the study and day 112.

Study design

This is a Phase 2, double-blind study, meaning neither you nor your doctor will know if you are receiving YA-101 or a placebo. It aims to enroll about 75 participants.

What's involved

You would take either YA-101 or a placebo twice a day. The study will track your health and any side effects until day 112.

Compensation

Not stated in the trial record.

Follow-up

The study will measure side effects from the start of the study until day 112.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.